LAUSR

To the Editor: Pulmonary carcinoid (PC) is a rare welldifferentiated neuroendocrine tumor that accounts for only approximately 2% of all malignant lung tumors. PCs are further divided by malignancy into lowand intermediate-grade malignant tumors, namely typical (TC) and atypical carcinoid (AC). Because of the low morbidity, there is a paucity of data on TC based on a large population or randomized controlled trials. According to recent guidelines and consensus statements, lobectomy or other anatomic resection procedures andmediastinal lymph node dissection or sampling are the standard treatment for stage I–II and resectable stage IIIAdisease, andadjuvant therapy is not recommended after complete resection; nevertheless, there is a lack of consensus on the treatment for unresectable stage III and metastatic disease, especially regarding the necessity of surgery and chemotherapy.